Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
501-520 of 1,307 trials

Myotonic Dystrophy Type I: Metformin Study

We are investigating whether metformin can improve muscle and overall function in patients with Myotonic Dystrophy Type I. The study will also assess the safety of metformin and its effects on quality of life.

Myotonic Dystrophy Type 1 (DM1)>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Hepatocellular Carcinoma: Durvalumab and Bevacizumab Study

We are studying whether the combination of durvalumab and bevacizumab can help prevent cancer recurrence in patients with hepatocellular carcinoma after surgery or ablation. This trial compares these treatments to a placebo to assess their effectiveness.

Early Stage Liver Cancer>2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteHepatologyOncology

Chronic Lymphocytic Leukemia: Pirtobrutinib vs. Ibrutinib

We are comparing the effectiveness of pirtobrutinib to ibrutinib in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. This study also focuses on those who are newly diagnosed and have a specific genetic change.

Chronic Lymphocytic Leukemia6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Deep Burns: Testing denovoSkin™ Graft

We are studying a new skin graft for patients with deep partial and full-thickness burns to see if it helps wounds heal and reduces scarring better than standard treatments. This trial aims to improve recovery outcomes for burn patients.

Deep Partial and Full-Thickness BurnsConfirmation phase (III)No PlaceboInvestigational MedicinesDermatology

MK-1084 with Pembrolizumab for Metastatic Lung Cancer

We are studying a new treatment combination for patients with KRAS G12C-mutant metastatic lung cancer. The goal is to see if it works better than standard treatment in improving survival and quality of life.

Non-small cell lung cancer>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementOncology

Coronary Artery Spasm: Testing Bosentan

We are studying whether the medication bosentan can help reduce coronary artery spasms in patients with ongoing angina symptoms. The trial also aims to evaluate its effects on quality of life and safety.

Coronary Vasospasm≤3 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Peripheral T-Cell Lymphoma: New Drug Combinations

We are studying whether combining Beleodaq or Folotyn with standard chemotherapy is more effective for newly diagnosed patients with Peripheral T-Cell Lymphoma. The goal is to see if these combinations improve treatment outcomes compared to standard therapy alone.

Peripheral T-Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Satralizumab for Pediatric Neuromyelitis Optica Spectrum Disorder

We are studying how well satralizumab works and its safety in children aged 2-11 with AQP4 antibody positive neuromyelitis optica spectrum disorder. This research aims to improve treatment options for these young patients.

Neuromyelitis Optica Spectrum Disorder (NMOSD)6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurologyPediatrics

Cannabidiol for Refractory Childhood Epilepsy

We are studying whether adding CBD can help children with hard-to-treat epilepsy manage their seizures better. The trial also looks at how this treatment affects the quality of life for patients and their families.

Refractory Epilepsy1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Hot Flashes After Breast Cancer: Oxybutynin vs. Venlafaxine

We are studying whether oxybutynin or venlafaxine is more effective in reducing hot flashes in women using endocrine therapy after breast cancer. We will also look at side effects and personal preferences between the two treatments.

Estrogen Receptor Positive Breast Cancer3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesEndocrinologyOncology

Immunoglobulin A Nephropathy: Ravulizumab Study

We are testing whether ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy. The study will also assess safety and quality of life compared to a placebo.

Immunoglobulin A Nephropathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Severe Systemic Lupus Erythematosus: Belimumab and Rituximab Study

We are investigating whether combining belimumab with rituximab can improve treatment outcomes for people with severe systemic lupus erythematosus. This study will compare this combination to standard treatments to see if it better reduces harmful autoantibodies and improves overall health.

Systemic Lupus Erythematosus>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

Multiple Myeloma: Elranatamab vs. Standard Treatments

We are studying a new treatment called elranatamab for people with relapsed refractory multiple myeloma. The goal is to see how well it works compared to current therapies and to assess its safety and impact on quality of life.

Relapsed/Refractory Multiple MyelomaConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Systemic Juvenile Idiopathic Arthritis: Baricitinib Study

We are studying the effectiveness of baricitinib in children aged 1 to under 18 with systemic juvenile idiopathic arthritis. This research aims to find out if it helps improve their condition.

Systemic Juvenile Idiopathic Arthritis6-12 monthsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Ovarian Cancer: Raludotatug Deruxtecan Study

We are studying a new drug for patients with platinum-resistant, high-grade ovarian cancer. The goal is to see if it works better than current treatment options.

Ovarian and Related Cancers>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Scabies Treatment: Comparing Permethrin Creams

We are testing whether a new 10% permethrin cream works better than the standard 5% cream for treating scabies. We will also look at the safety of the new cream.

Scabies>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyInfectious Diseases

Methylphenidate for Cancer-Related Fatigue in Young Brain Tumor Survivors

We are studying whether methylphenidate can help reduce fatigue in patients who were treated for brain tumors during childhood or adolescence. Additionally, we will look at its effects on sleep, cognitive function, and quality of life.

Cancer-related Fatigue after Pediatric Brain Tumor Treatment3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementOncologyPediatrics

Quizartinib for Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

We are studying whether quizartinib, combined with chemotherapy, can improve survival in adults with newly diagnosed FLT3-ITD negative AML compared to a placebo. This trial aims to assess its effectiveness and safety.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementOncology

Biliary Tract Cancers: [18F]F-FAPI PET-CT Imaging Study

We are investigating how a new imaging technique may improve diagnosis and treatment planning for patients with potentially resectable biliary tract cancers. This study will also look at the cost-effectiveness and safety of this imaging method.

Cholangiocarcinoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyOncology

Chronic Lymphocytic Leukemia: Lisaftoclax Treatment Study

We are studying whether a new drug, lisaftoclax, combined with another treatment, helps patients with chronic lymphocytic leukemia who have been previously treated. The goal is to see if this combination improves survival and slows disease progression.

Chronic Lymphocytic Leukemia (CLL) / Small Cell Lymphocytic Lymphoma (SLL)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology